Edition:
United States

Moleculin Biotech Inc (MBRX.OQ)

MBRX.OQ on NASDAQ Stock Exchange Capital Market

1.39USD
16 Nov 2018
Change (% chg)

$0.01 (+0.72%)
Prev Close
$1.38
Open
$1.39
Day's High
$1.39
Day's Low
$1.34
Volume
16,004
Avg. Vol
16,586
52-wk High
$3.33
52-wk Low
$1.04

Latest Key Developments (Source: Significant Developments)

Moleculin Enters Agreement With BSP Pharmaceuticals For Its Leukemia Drug Candidate
Tuesday, 24 Apr 2018 08:30am EDT 

April 24 (Reuters) - Moleculin Biotech Inc ::MOLECULIN ENTERS AGREEMENT WITH BSP PHARMACEUTICALS FOR ITS LEUKEMIA DRUG CANDIDATE.MOLECULIN BIOTECH INC - ENGAGED BSP PHARMACEUTICALS S.P.A. TO BEGIN PREPARATIONS FOR COMMERCIAL SCALE PRODUCTION OF ANNAMYCIN DRUG PRODUCT.  Full Article

Moleculin Biotech Reports Financial Results For The Year Ended Dec 31, 2017
Wednesday, 28 Mar 2018 08:30am EDT 

March 28 (Reuters) - Moleculin Biotech Inc ::MOLECULIN BIOTECH, INC. REPORTS FINANCIAL RESULTS FOR THE YEAR ENDED DECEMBER 31, 2017.MOLECULIN BIOTECH - BELIEVES EXISTING CASH & CASH EQUIVALENTS AS OF DECEMBER 31, 2017, OTHER CASH, WILL BE SUFFICIENT TO FUND PLANNED OPERATIONS INTO Q1 2019.  Full Article

Moleculin Announces Pricing Of $9 Million Registered Direct Offering
Friday, 16 Feb 2018 08:29am EST 

Feb 16 (Reuters) - Moleculin Biotech Inc ::MOLECULIN ANNOUNCES PRICING OF $9 MILLION REGISTERED DIRECT OFFERING.MOLECULIN BIOTECH - ‍IN CONNECTION WITH OFFERING, CO WILL ISSUE 4.3 MILLION REGISTERED SHARES OF COMMON STOCK AT A PURCHASE PRICE OF $2.10 PER SHARE​.  Full Article

Moleculin Announces Discovery Of A New Molecule For Cancer Treatment
Thursday, 15 Feb 2018 08:30am EST 

Feb 15 (Reuters) - Moleculin Biotech Inc ::MOLECULIN BIOTECH INC - ANNOUNCES BREAKTHROUGH IN ITS EFFORT TO DEVELOP A NEW CANCER TREATMENT THAT SELECTIVELY KILLS HIGHLY RESISTANT TUMORS​.  Full Article

Moleculin Announces Polish Approval For Leukemia Clinical Trial
Thursday, 21 Dec 2017 08:30am EST 

Dec 21 (Reuters) - Moleculin Biotech Inc ::MOLECULIN ANNOUNCES POLISH APPROVAL FOR LEUKEMIA CLINICAL TRIAL.MOLECULIN BIOTECH - ETHICS COMMITTEE IN POLAND HAS APPROVED COMPANY'S PHASE I/II CLINICAL TRIAL OF ANNAMYCIN FOR TREATMENT OF LEUKEMIA.MOLECULIN BIOTECH INC - COMPANY EXPECTS FIRST PATIENT TO BE ENROLLED IN Q1 2018.MOLECULIN BIOTECH - BELIEVES CLINICAL DATA PRODUCED IN POLAND WILL BE USEFUL IN INTERACTIONS WITH U.S. FDA, EUROPEAN MEDICINES AGENCY.  Full Article

Moleculin's WP1066 Drug Gets FDA Brain Tumor IND Clearance
Tuesday, 5 Dec 2017 07:00am EST 

Dec 5 (Reuters) - Moleculin Biotech Inc ::MOLECULIN'S WP1066 DRUG GETS FDA BRAIN TUMOR IND CLEARANCE.MOLECULIN BIOTECH-IND APPLICATION FOR PHASE I TRIAL OF WP1066 IN PATIENTS WITH RECURRENT MALIGNANT GLIOMA, BRAIN METASTASIS FROM MELANOMA, ALLOWED BY FDA.  Full Article

Moleculin Biotech Says Co Was Informed That Investigational NDA For Phase I Trial Of WP1066 Has Been Allowed By FDA
Monday, 4 Dec 2017 07:40am EST 

Dec 4 (Reuters) - Moleculin Biotech Inc ::MOLECULIN BIOTECH SAYS ON NOV 29, CO WAS INFORMED THAT INVESTIGATIONAL NDA FOR PHASE I TRIAL OF WP1066 HAS BEEN ALLOWED BY FDA - SEC FILING.  Full Article

Moleculin Biotech Q3 loss per share $0.14‍​
Tuesday, 14 Nov 2017 07:00am EST 

Nov 14 (Reuters) - Moleculin Biotech Inc : :Moleculin Biotech Inc reports financial results for the third quarter ended september 30, 2017.Moleculin Biotech Inc - qtrly loss per share $0.14‍​.  Full Article

Moleculin announces MD Anderson has filed an IND with the FDA on its drug WP1066 for the treatment of brain tumors
Wednesday, 1 Nov 2017 07:30am EDT 

Nov 1 (Reuters) - Moleculin Biotech Inc :Moleculin announces MD Anderson has filed an IND with the FDA on its drug WP1066 for the treatment of brain tumors.Moleculin-Responses to FDA requests for more information regarding physician-sponsored ind for WP1066 as potential treatment for brain tumors submitted​.  Full Article

Moleculin requests for clinical trial authorization to study annamycin
Tuesday, 24 Oct 2017 07:30am EDT 

Oct 24 (Reuters) - Moleculin Biotech Inc ::Moleculin Biotech - ‍submitted request for clinical trial authorization to study annamycin for treating relapsed/refractory acute myeloid leukemia in Poland.  Full Article